Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger
--Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet Medical Need--
--Broad-Based Investor Syndicate to Vote in Favor of the Merger and Provide Concurrent Financing of Approximately $22 Million--
--Companies to Host Conference Call Today at 8:30 a.m. ET--
CAMBRIDGE, Mass. and VANCOUVER, British Columbia, June 15, 2016 -- Aegerion Pharmaceuticals, Inc. (AEGR) (“Aegerion”) and QLT Inc. (QLTI) (QLT.TO) (“QLT”) today announced that they have entered into a definitive merger agreement under which Aegerion will be merged with a wholly owned indirect subsidiary of QLT. Upon completion of the proposed merger, each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of QLT common stock. QLT plans to change its name upon the closing of the proposed transaction to Novelion Therapeutics Inc. (“Novelion”) and its common shares will trade on the NASDAQ Global Select Market and the Toronto Stock Exchange.
- Published: 15 June 2016
- Written by Editor